These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1026 related articles for article (PubMed ID: 16818854)

  • 1. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.
    Duggan C; Marriott K; Edwards R; Cuzick J
    J Clin Oncol; 2003 Oct; 21(19):3588-93. PubMed ID: 14512389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.
    Decensi A; Maisonneuve P; Rotmensz N; Bettega D; Costa A; Sacchini V; Salvioni A; Travaglini R; Oliviero P; D'Aiuto G; Gulisano M; Gucciardo G; del Turco MR; Pizzichetta MA; Conforti S; Bonanni B; Boyle P; Veronesi U;
    Circulation; 2005 Feb; 111(5):650-6. PubMed ID: 15699284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
    Garber JE; Halabi S; Tolaney SM; Kaplan E; Archer L; Atkins JN; Edge S; Shapiro CL; Dressler L; Paskett ED; Kimmick G; Orcutt J; Scalzo A; Winer E; Levine E; Shahab N; Berliner N;
    J Natl Cancer Inst; 2010 Jul; 102(13):942-9. PubMed ID: 20554945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus.
    Dizon-Townson D; Miller C; Sibai B; Spong CY; Thom E; Wendel G; Wenstrom K; Samuels P; Cotroneo MA; Moawad A; Sorokin Y; Meis P; Miodovnik M; O'Sullivan MJ; Conway D; Wapner RJ; Gabbe SG;
    Obstet Gynecol; 2005 Sep; 106(3):517-24. PubMed ID: 16135581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.
    De Stefano V; Martinelli I; Mannucci PM; Paciaroni K; Chiusolo P; Casorelli I; Rossi E; Leone G
    N Engl J Med; 1999 Sep; 341(11):801-6. PubMed ID: 10477778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke risk and tamoxifen therapy for breast cancer.
    Geiger AM; Fischberg GM; Chen W; Bernstein L
    J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
    Swerdlow AJ; Jones ME;
    J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma.
    Pihusch R; Danzl G; Scholz M; Harich D; Pihusch M; Lohse P; Hiller E
    Cancer; 2002 Jun; 94(12):3120-6. PubMed ID: 12115343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations.
    DeSancho MT; Berlus N; Christos PJ; Rand J
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):11-5. PubMed ID: 19474699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Bavarian Thromboembolic Risk Cohort Study (BATER). Study protocol, state of the investigation and first results].
    Schramm W; Heinemann LA; Spannagl M; Dick A; Assmann A
    Dtsch Med Wochenschr; 2000 Jan; 125(1-2):2-6. PubMed ID: 10650817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: a hospital-based case-control study.
    Oger E; Lacut K; Le Gal G; Couturaud F; Abalain JH; Mercier B; Mottier D;
    Thromb Res; 2007; 120(2):207-14. PubMed ID: 17126889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
    Weitz IC; Israel VK; Liebman HA
    Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor V Leiden and prothrombin 20210 G-A mutations in controls and in patients with thromboembolic events during pregnancy or the puerperium.
    Yilmazer M; Kurtay G; Sonmezer M; Akar N
    Arch Gynecol Obstet; 2003 Oct; 268(4):304-8. PubMed ID: 14504875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor V Leiden and prothrombin gene G20210A mutation in children with venous thromboembolism.
    Bonduel M; Hepner M; Sciuccati G; Pieroni G; Feliú-Torres A; Mardaraz C; Frontroth JP
    Thromb Haemost; 2002 Jun; 87(6):972-7. PubMed ID: 12083504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.